Mibavademab clinical trials
Also written REGN4461.
How each study uses mibavademab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mibavademab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test mibavademab, phase 3 first.
- Jun 2027A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and AdultsPhase 3 · Regeneron Pharmaceuticals
Studies
Open first, then newest update. How each study uses mibavademab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic AmenorrheaRecruitingPhase 2Regeneron PharmaceuticalsNCT07235917Written as Mibavademab
- Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized LipodystrophyRecruitingPhase 3Regeneron PharmaceuticalsNCT07220785Written as Mibavademab
- A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and AdultsRecruitingPhase 3Regeneron PharmaceuticalsNCT07220772Written as Mibavademab
- A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)CompletedPhase 3Regeneron PharmaceuticalsNCT06548100Written as mibavademab
- Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized LipodystrophyCompletedPhase 2Regeneron PharmaceuticalsNCT04159415Written as Low-Dose REGN4461
- A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With ObesityCompletedPhase 2Eli Lilly and CompanyNCT06373146Written as Mibavademab
- A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)TerminatedPhase 2Regeneron PharmaceuticalsNCT05088460Written as REGN4461
- A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy VolunteersCompletedPhase 1Regeneron PharmaceuticalsNCT03530514Written as REGN4461
Codes
What other systems call mibavademab · ClinicalTrials.gg INT017587
- UNII (FDA) PHL2UDY3ABMIBAVADEMABOne source FDA
- NCI Thesaurus C179103MibavademabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PHL2UDY3AB | MIBAVADEMAB | One source FDA |
| NCI Thesaurus | C179103 | Mibavademab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.